Search

Your search keyword '"Blumenfeld, Andrew"' showing total 597 results
Start Over Author "Blumenfeld, Andrew"
597 results on '"Blumenfeld, Andrew"'

9. Performance of polygenic risk scores for cancer prediction in a racially diverse academic biobank

Author

Abecasis, Goncalo, Bai, Xiaodong, Balasubramanian, Suganthi, Baras, Aris, Blumenfeld, Andrew, Boutkov, Boris, Cantor, Michael, Coppola, Giovanni, Economides, Aris, Eom, Gisu, Habegger, Lukas, Hawes, Alicia, Jones, Marcus B., Khalid, Shareef, Krasheninina, Olga, Lanche, Rouel, Lotta, Luca A., Mansfield, Adam J., Maxwell, Evan K., Mighty, Jason, Mitnaul, Lyndon J., Nafde, Mrunali, O’Keeffe, Sean, Orelus, Max, Overton, John D., Panea, Razvan, Polanco, Tommy, Rasool, Ayesha, Reid, Jeffrey G., Salerno, William, Staples, Jeffrey C., Shuldiner, Alan, Beechert, Christina, Forsythe, Caitlin, Fuller, Erin D., Gu, Zhenhua, Lattari, Michael, Lopez, Alexander, Manoochehri, Kia, Pradhan, Manasi, Schleicher, Thomas D., Padilla, Maria Sotiropoulos, Ulloa, Ricardo H., Widom, Louis, Wolf, Sarah E., Wang, Louise, Desai, Heena, Verma, Shefali S., Le, Anh, Hausler, Ryan, Verma, Anurag, Judy, Renae, Doucette, Abigail, Gabriel, Peter E., Nathanson, Katherine L., Damrauer, Scott M., Mowery, Danielle L., Ritchie, Marylyn D., Kember, Rachel L., and Maxwell, Kara N.

Published
2022
Full Text
View/download PDF

15. Genetic Susceptibility to Mood Disorders and Risk of Stroke: A Polygenic Risk Score and Mendelian Randomization Study

Author

Sun, Jiangming, Borné, Yan, Edsfeldt, Andreas, Wang, Yunpeng, Pan, Mengyu, Melander, Olle, Engström, Gunnar, Gonçalves, Isabel, Abecasis, Goncalo, Baras, Aris, Cantor, Michael, Coppola, Giovanni, Economides, Aris, Lotta, Luca A., Overton, John D., Reid, Jeffrey G., Shuldiner, Alan, Beechert, Christina, Forsythe, Caitlin, Fuller, Erin D., Gu, Zhenhua, Lattari, Michael, Lopez, Alexander, Overton, John D., Schleicher, Thomas D., Padilla, Maria Sotiropoulos, Toledo, Karina, Widom, Louis, Wolf, Sarah E., Pradhan, Manasi, Manoochehri, Kia, Ulloa, Ricardo H., Bai, Xiaodong, Balasubramanian, Suganthi, Barnard, Leland, Blumenfeld, Andrew, Eom, Gisu, Habegger, Lukas, Hahn, Young, Hawes, Alicia, Khalid, Shareef, Reid, Jeffrey G., Maxwell, Evan K., Salerno, William, Staples, Jeffrey C., Yadav, Ashish, Jones, Marcus B., and Mitnaul, Lyndon J.

Published
2023
Full Text
View/download PDF

16. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs

Author

Siminovitch, Katherine A., Hirschfield, Gideon M., Mason, Andrew, Vincent, Catherine, Xie, Gang, Zhang, Jinyi, Tang, Ruqi, Ma, Xiong, Li, Zhiqiang, Shi, Yongyong, Affronti, Andrea, Almasio, Piero L., Alvaro, Domenico, Andreone, Pietro, Andriulli, Angelo, Azzaroli, Francesco, Battezzati, Pier Maria, Benedetti, Antonio, Bragazzi, MariaConsiglia, Brunetto, Maurizia, Bruno, Savino, Calvaruso, Vincenza, Cardinale, Vincenzo, Casella, Giovanni, Cazzagon, Nora, Ciaccio, Antonio, Coco, Barbara, Colli, Agostino, Colloredo, Guido, Colombo, Massimo, Colombo, Silvia, Cristoferi, Laura, Cursaro, Carmela, Crocè, Lory Saveria, Crosignani, Andrea, D’Amato, Daphne, Donato, Francesca, Elia, Gianfranco, Fabris, Luca, Fagiuoli, Stefano, Ferrari, Carlo, Floreani, Annarosa, Galli, Andrea, Giannini, Edoardo, Grattagliano, Ignazio, Lampertico, Pietro, Lleo, Ana, Malinverno, Federica, Mancuso, Clara, Marra, Fabio, Marzioni, Marco, Massironi, Sara, Mattalia, Alberto, Miele, Luca, Milani, Chiara, Morini, Lorenzo, Morisco, Filomena, Muratori, Luigi, Muratori, Paolo, Niro, Grazia A., O’Donnell, Sarah, Picciotto, Antonio, Portincasa, Piero, Rigamonti, Cristina, Ronca, Vincenzo, Rosina, Floriano, Spinzi, Giancarlo, Strazzabosco, Mario, Tarocchi, Mirko, Tiribelli, Claudio, Toniutto, Pierluigi, Valenti, Luca, Vinci, Maria, Zuin, Massimo, Nakamura, Hitomi, Abiru, Seigo, Nagaoka, Shinya, Komori, Atsumasa, Yatsuhashi, Hiroshi, Ishibashi, Hiromi, Ito, Masahiro, Migita, Kiyoshi, Ohira, Hiromasa, Katsushima, Shinji, Naganuma, Atsushi, Sugi, Kazuhiro, Komatsu, Tatsuji, Mannami, Tomohiko, Matsushita, Kouki, Yoshizawa, Kaname, Makita, Fujio, Nikami, Toshiki, Nishimura, Hideo, Kouno, Hiroshi, Kouno, Hirotaka, Ota, Hajime, Komura, Takuya, Nakamura, Yoko, Shimada, Masaaki, Hirashima, Noboru, Komeda, Toshiki, Ario, Keisuke, Nakamuta, Makoto, Yamashita, Tsutomu, Furuta, Kiyoshi, Kikuchi, Masahiro, Naeshiro, Noriaki, Takahashi, Hironao, Mano, Yutaka, Tsunematsu, Seiji, Yabuuchi, Iwao, Shimada, Yusuke, Yamauchi, Kazuhiko, Sugimoto, Rie, Sakai, Hironori, Mita, Eiji, Koda, Masaharu, Tsuruta, Satoru, Kamitsukasa, Hiroshi, Sato, Takeaki, Masaki, Naohiko, Kobata, Tatsuro, Fukushima, Nobuyoshi, Ohara, Yukio, Muro, Toyokichi, Takesaki, Eiichi, Takaki, Hitoshi, Yamamoto, Tetsuo, Kato, Michio, Nagaoki, Yuko, Hayashi, Shigeki, Ishida, Jinya, Watanabe, Yukio, Kobayashi, Masakazu, Koga, Michiaki, Saoshiro, Takeo, Yagura, Michiyasu, Hirata, Keisuke, Tanaka, Atsushu, Takikawa, Hajime, Zeniya, Mikio, Abe, Masanori, Onji, Morikazu, Kaneko, Shuichi, Honda, Masao, Arai, Kuniaki, Arinaga-Hino, Teruko, Hashimoto, Etsuko, Taniai, Makiko, Umemura, Takeji, Joshita, Satoru, Nakao, Kazuhiko, Ichikawa, Tatsuki, Shibata, Hidetaka, Yamagiwa, Satoshi, Seike, Masataka, Honda, Koichi, Sakisaka, Shotaro, Takeyama, Yasuaki, Harada, Masaru, Senju, Michio, Yokosuka, Osamu, Kanda, Tatsuo, Ueno, Yoshiyuki, Kikuchi, Kentaro, Ebinuma, Hirotoshi, Himoto, Takashi, Yasunami, Michio, Murata, Kazumoto, Mizokami, Masashi, Kawata, Kazuhito, Shimoda, Shinji, Miyake, Yasuhiro, Takaki, Akinobu, Yamamoto, Kazuhide, Hirano, Katsuji, Ichida, Takafumi, Ido, Akio, Tsubouchi, Hirohito, Chayama, Kazuaki, Harada, Kenichi, Nakanuma, Yasuni, Maehara, Yoshihiko, Taketomi, Akinobu, Shirabe, Ken, Soejima, Yuji, Mori, Akira, Yagi, Shintaro, Uemoto, Shinji, H, Egawa, Tanaka, Tomohiro, Yamashiki, Noriyo, Tamura, Sumito, Sugawara, Yasuhiro, Kokudo, Norihiro, Juran, Brian D., Atkinson, Elizabeth J., Cheung, Angela, de Andrade, Mariza, Lazaridis, Konstantinos N., Chalasani, Naga, Luketic, Vel, Odin, Joseph, Chopra, Kapil, Baras, Aris, Horowitz, Julie, Abecasis, Goncalo, Cantor, Michael, Coppola, Giovanni, Economides, Aris, Lotta, Luca A., Overton, John D., Reid, Jeffrey G., Shuldiner, Alan, Beechert, Christina, Forsythe, Caitlin, Fuller, Erin D., Gu, Zhenhua, Lattari, Michael, Lopez, Alexander, Schleicher, Thomas D., Padilla, Maria Sotiropoulos, Toledo, Karina, Widom, Louis, Wolf, Sarah E., Pradhan, Manasi, Manoochehri, Kia, Ulloa, Ricardo H., Bai, Xiaodong, Balasubramanian, Suganthi, Barnard, Leland, Blumenfeld, Andrew, Eom, Gisu, Habegger, Lukas, Hawes, Alicia, Khalid, Shareef, Maxwell, Evan K., Salerno, William, Staples, Jeffrey C., Jones, Marcus B., Mitnaul, Lyndon J., Sturgess, Richard, Healey, Christopher, Yeoman, Andrew, Gunasekera, Anton VJ., Kooner, Paul, Kapur, Kapil, Sathyanarayana, V., Kallis, Yiannis, Subhani, Javaid, Harvey, Rory, McCorry, Roger, Rooney, Paul, Ramanaden, David, Evans, Richard, Mathialahan, Thiriloganathan, Gasem, Jaber, Shorrock, Christopher, Bhalme, Mahesh, Southern, Paul, Tibble, Jeremy A., Gorard, David A., Jones, Susan, Mells, George, Mulcahy, Victoria, Srivastava, Brijesh, Foxton, Matthew R., Collins, Carole E., Elphick, David, Karmo, Mazn, Porras-Perez, Francisco, Mendall, Michael, Yapp, Tom, Patel, Minesh, Ede, Roland, Sayer, Joanne, Jupp, James, Fisher, Neil, Carter, Martyn J., Koss, Konrad, Shah, Jayshri, Piotrowicz, Andrzej, Scott, Glyn, Grimley, Charles, Gooding, Ian R., Williams, Simon, Tidbury, Judith, Lim, Guan, Cheent, Kuldeep, Levi, Sass, Mansour, Dina, Beckley, Matilda, Hollywood, Coral, Wong, Terry, Marley, Richard, Ramage, John, Gordon, Harriet M., Ridpath, Jo, Ngatchu, Theodore, Bob Grover, Vijay Paul, Shidrawi, Ray G., Abouda, George, Corless, L., Narain, Mark, Rees, Ian, Brown, Ashley, Taylor-Robinson, Simon, Wilkins, Joy, Grellier, Leonie, Banim, Paul, Das, Debasish, Heneghan, Michael A., Curtis, Howard, Matthews, Helen C., Mohammed, Faiyaz, Aldersley, Mark, Srirajaskanthan, Raj, Walker, Giles, McNair, Alistair, Sharif, Amar, Sen, Sambit, Bird, George, Prince, Martin I., Prasad, Geeta, Kitchen, Paul, Barnardo, Adrian, Oza, Chirag, Sivaramakrishnan, Nurani N., Gupta, Prakash, Shah, Amir, Evans, Chris DJ., Saha, Subrata, Pollock, Katharine, Bramley, Peter, Mukhopadhya, Ashis, Barclay, Stephen T., McDonald, Natasha, Bathgate, Andrew J., Palmer, Kelvin, Dillon, John F., Rushbrook, Simon M., Przemioslo, Robert, McDonald, Chris, Millar, Andrew, Tai, Cheh, Mitchell, Stephen, Metcalf, Jane, Shaukat, Syed, Ninkovic, Mary, Shmueli, Udi, Davis, Andrew, Naqvi, Asifabbas, Lee, Tom JW., Ryder, Stephen, Collier, Jane, Klass, Howard, Cramp, Matthew E., Sharer, Nichols, Aspinall, Richard, Ghosh, Deb, Douds, Andrew C., Booth, Jonathan, Williams, Earl, Hussaini, Hyder, Christie, John, Mann, Steven, Thorburn, Douglas, Marshall, Aileen, Patanwala, Imran, Ala, Aftab, Maltby, Julia, Matthew, Ray, Corbett, Chris, Vyas, Sam, Singhal, Saket, Gleeson, Dermot, Misra, Sharat, Butterworth, Jeff, George, Keith, Harding, Tim, Douglass, Andrew, Mitchison, Harriet, Panter, Simon, Shearman, Jeremy, Bray, Gary, Roberts, Michael, Butcher, Graham, Forton, Daniel, Mahmood, Zahid, Cowan, Matthew, Das, Debashis, Ch’ng, Chin Lye, Rahman, Mesbah, Whatley, Gregory C.A., Wesley, Emma, Mandal, Aditya, Jain, Sanjiv, Pereira, Stephen P., Wright, Mark, Trivedi, Palak, Gordon, Fiona H., Unitt, Esther, Palejwala, Altaf, Austin, Andrew, Vemala, Vishwaraj, Grant, Allister, Higham, Andrew D., Brind, Alison, Mathew, Ray, Cox, Mark, Ramakrishnan, Subramaniam, King, Alistair, Whalley, Simon, Fraser, Jocelyn, Thomson, S.J., Bell, Andrew, Wong, Voi Shim, Kia, Richard, Gee, Ian, Keld, Richard, Ransford, Rupert, Gotto, James, Millson, Charles, Cordell, Heather J., Fryett, James J., Ueno, Kazuko, Darlay, Rebecca, Aiba, Yoshihiro, Hitomi, Yuki, Kawashima, Minae, Nishida, Nao, Khor, Seik-Soon, Gervais, Olivier, Kawai, Yosuke, Nagasaki, Masao, Tokunaga, Katsushi, Gerussi, Alessio, Carbone, Marco, Asselta, Rosanna, Ferreira, Manuel A.R., Sun, Dylan, Jones, David E., Flack, Steven, Spicer, Ann, Mulcahy, Victoria L., Byan, Jinyoung, Han, Younghun, Sandford, Richard N., Amos, Christopher I., Seldin, Michael F., Invernizzi, Pietro, Nakamura, Minoru, and Mells, George F.

Published
2021
Full Text
View/download PDF

17. Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline

Author

Alizadeh, Behrooz Z., Boezen, H. Marike, Franke, Lude, van der Harst, Pim, Navis, Gerjan, Rots, Marianne, Snieder, Harold, Swertz, Morris, Wolffenbuttel, Bruce H.R., Wijmenga, Cisca, Abecasis, Goncalo, Baras, Aris, Cantor, Michael, Coppola, Giovanni, Economides, Aris, Lotta, Luca A., Overton, John D., Reid, Jeffrey G., Shuldiner, Alan, Beechert, Christina, Forsythe, Caitlin, Fuller, Erin D., Gu, Zhenhua, Lattari, Michael, Lopez, Alexander, Schleicher, Thomas D., Padilla, Maria Sotiropoulos, Toledo, Karina, Widom, Louis, Wolf, Sarah E., Pradhan, Manasi, Manoochehri, Kia, Ulloa, Ricardo H., Bai, Xiaodong, Balasubramanian, Suganthi, Barnard, Leland, Blumenfeld, Andrew, Eom, Gisu, Habegger, Lukas, Hawes, Alicia, Khalid, Shareef, Maxwell, Evan K., Salerno, William, Staples, Jeffrey C., Jones, Marcus B., Mitnaul, Lyndon J., Gorski, Mathias, Jung, Bettina, Li, Yong, Matias-Garcia, Pamela R., Wuttke, Matthias, Coassin, Stefan, Thio, Chris H.L., Kleber, Marcus E., Winkler, Thomas W., Wanner, Veronika, Chai, Jin-Fang, Chu, Audrey Y., Cocca, Massimiliano, Feitosa, Mary F., Ghasemi, Sahar, Hoppmann, Anselm, Horn, Katrin, Li, Man, Nutile, Teresa, Scholz, Markus, Sieber, Karsten B., Teumer, Alexander, Tin, Adrienne, Wang, Judy, Tayo, Bamidele O., Ahluwalia, Tarunveer S., Almgren, Peter, Bakker, Stephan J.L., Banas, Bernhard, Bansal, Nisha, Biggs, Mary L., Boerwinkle, Eric, Bottinger, Erwin P., Brenner, Hermann, Carroll, Robert J., Chalmers, John, Chee, Miao-Li, Chee, Miao-Ling, Cheng, Ching-Yu, Coresh, Josef, de Borst, Martin H., Degenhardt, Frauke, Eckardt, Kai-Uwe, Endlich, Karlhans, Franke, Andre, Freitag-Wolf, Sandra, Gampawar, Piyush, Gansevoort, Ron T., Ghanbari, Mohsen, Gieger, Christian, Hamet, Pavel, Ho, Kevin, Hofer, Edith, Holleczek, Bernd, Xian Foo, Valencia Hui, Hutri-Kähönen, Nina, Hwang, Shih-Jen, Ikram, M. Arfan, Josyula, Navya Shilpa, Kähönen, Mika, Khor, Chiea-Chuen, Koenig, Wolfgang, Kramer, Holly, Krämer, Bernhard K., Kühnel, Brigitte, Lange, Leslie A., Lehtimäki, Terho, Lieb, Wolfgang, Loos, Ruth J.F., Lukas, Mary Ann, Lyytikäinen, Leo-Pekka, Meisinger, Christa, Meitinger, Thomas, Melander, Olle, Milaneschi, Yuri, Mishra, Pashupati P., Mononen, Nina, Mychaleckyj, Josyf C., Nadkarni, Girish N., Nauck, Matthias, Nikus, Kjell, Ning, Boting, Nolte, Ilja M., O’Donoghue, Michelle L., Orho-Melander, Marju, Pendergrass, Sarah A., Penninx, Brenda W.J.H., Preuss, Michael H., Psaty, Bruce M., Raffield, Laura M., Raitakari, Olli T., Rettig, Rainer, Rheinberger, Myriam, Rice, Kenneth M., Rosenkranz, Alexander R., Rossing, Peter, Rotter, Jerome I., Sabanayagam, Charumathi, Schmidt, Helena, Schmidt, Reinhold, Schöttker, Ben, Schulz, Christina-Alexandra, Sedaghat, Sanaz, Shaffer, Christian M., Strauch, Konstantin, Szymczak, Silke, Taylor, Kent D., Tremblay, Johanne, Chaker, Layal, van der Most, Peter J., Verweij, Niek, Völker, Uwe, Waldenberger, Melanie, Wallentin, Lars, Waterworth, Dawn M., White, Harvey D., Wilson, James G., Wong, Tien-Yin, Woodward, Mark, Yang, Qiong, Yasuda, Masayuki, Yerges-Armstrong, Laura M., Zhang, Yan, Wanner, Christoph, Böger, Carsten A., Köttgen, Anna, Kronenberg, Florian, Pattaro, Cristian, and Heid, Iris M.

Published
2021
Full Text
View/download PDF

18. Polygenic Risk of Psychiatric Disorders Exhibits Cross-trait Associations in Electronic Health Record Data From European Ancestry Individuals

Author

Abecasis, Goncalo, Baras, Aris, Cantor, Michael, Coppola, Giovanni, Economides, Aris, Lotta, Luca, Overton, John D., Reid, Jeffrey G., Shuldiner, Alan, Beechert, Christina, Forsythe, Caitlin, Fuller, Erin D., Gu, Zhenhua, Lattari, Michael, Lopez, Alexander, Schleicher, Thomas D., Padilla, Maria Sotiropoulos, Toledo, Karina, Widom, Louis, Wolf, Sarah E., Pradhan, Manasi, Manoochehri, Kia, Ulloa, Ricardo H., Bai, Xiaodong, Balasubramanian, Suganthi, Barnard, Leland, Blumenfeld, Andrew, Eom, Gisu, Habegger, Lukas, Hahn, Young, Hawes, Alicia, Khalid, Shareef, Maxwell, Evan K., Salerno, William, Staples, Jeffrey C., Yadav, Ashish, Jones, Marcus B., Mitnaul, Lyndon J., Kember, Rachel L., Merikangas, Alison K., Verma, Shefali S., Verma, Anurag, Judy, Renae, Damrauer, Scott M., Ritchie, Marylyn D., Rader, Daniel J., and Bućan, Maja

Published
2021
Full Text
View/download PDF

19. Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial

Author

Muñoz, Daniel Julio, Amor, Jorge David, Bocchiardo, Carolina, Danielle, Julieta Iourno, Laffue, Alfredo, Obregon, Carolina Daniela Diaz, Paez, Maria Fernanda, Perez, Roberto Martin, Rocchi, Viviana Ana Maria, Teijeiro, Loreley Deborah, Gómez, Jesica, Villa, Andres Maria, Aguirre, Florencia, Fernández, Victoria Carla, Goicoechea, Ramon F., Melamud, Luciana, Stillman, Ana, de Virgiliis, Mariana, Cassara, Fatima Pagani, Cordoba, Marta, Gutierrez, Maria Teresa, Ingolotti, Mariana, Larripa, Natalia, Lupinacci, Anahi, Arroyo, Josefina, Romano, Alejandra, Torres, Mariana Foa, Ballario, Carlos Héctor, Chiesa, Ana Elisa, Gómez, Hernán Gustavo, Lattini, Hernán Gabriel, Mainella, Carolina Natalia, Bolner, Gisel Edith, Eschoyez, María Soledad, Broadley, Simon Andrew, Heshmat, Saman, Sabet, Arman, Swayne, Andrew, Freeman, Susan, Sanchez, Sofia Jimenez, Shuey, Neil, Dalic, Linda, French, Ann, Kuma, Guru, Laing, Joshua, Law, Lai Yin, MacIntyre, Jennifer, Neal, Andrew, Plummer, Christopher, Ramachandran, Prashanth, Sedal, Leslie, Wilson, Ian, Winkel, Antony, Zhang, Wenwen, Chen, Tina, Watts, Rani, Barnett, Michael, Barton, Joshua, Beadnall, Heidi, Garber, Justin, Hardy, Todd Andrew, Trewin, Benjamin, Taha, Marinda, Walters, Deleni, Sieger, Federico Arturo Silva, Alfonso, Nhora Patricia Ruiz, Camacho, Anna Maria Pinzon, Moreno, Alexander Pabón, Prad, Jorge Armando Castellanos, Rueda, Adriana Paola Duarte, Castillo, Tatiana, Gonzalez, Karol Melissa Castillo, Pico, Martha Yolanda Moreno, Castill, Judith, Habek, Mario, Adamec, Ivan, Barun, Barbara, Crnosija, Luka, Gabelic, Tereza, Nytrova, Petra, Krasulova, Eva, Pavlickova, Jana, Tyblova, Michaela, Zubkova, Jana, Petersen, Thor, Dale, Gro Helen, Rasmussen, Peter Vestergaard, Stilund, Morten, Svendsen, Kristina Bacher, Brandt, Vivi, Collongues, Nicolas, Fleury, Marie-Celine, Kremer, Laurent, Bendele, Sandrine, Neff, Valérie, Diem, Ricarda, Platten, Michael, Berberich, Anne, Jansen, Jonabelle, Jaschoneck, Hannah, Wildemann, Brigitte, Aures, Ursula, Brandenburger, Tanja, Haut, Tanja, Fernández, Maria-Lourdes Treceno, Aly, Lilian, Brinkhoff, Kirsten, Buck, Dorothea, Golkowski, Daniel, Hermisson, Mirjam, Hoshi, Muna-Miriam, Kaminski, Miriam, Kowarik, Markus Christian, Kronsbein, Helena, Lehmann-Horn, Klaus, Pongratz, Viola Maria, Schweiker, Andreas, Leddy, Lisa-Ann, Mueller, Silvia, Obergfell, Kim, Wanka, Marion, Zettl, Uwe Klaus, Klinke, Jan, Loebermann, Micha, Meister, Stefanie, Rimmele, Florian, Winkelmann, Alexander, Schroeder, Ina, Lau, Alexander Yuk-Lun, Au, Lisa Wing-Chi, Fan, Florence Sin-Ying, Ip, Vincent Hing-Lung, Ma, Karen Ka-Yan, Ma, Sze-Ho, Mok, Vincent Chung-Tong, Au, Cheryl Chung-Kwan, Kwan, Pauline Wing-Lam, Patti, Francesco, Caramma, Andrea Salvatore, Chisari, Clara Grazia, Fermo, Salvatore Lo, Messina, Silvia, Projetto, Maria, Caserta, Cinzia, Filla, Alessandro, Costabile, Teresa, Pane, Chiara, Sacca, Francesco, Marsili, Angela, Puorro, Giorgia, Bergamaschi, Roberto, Berra, Eliana, Mallucci, Giulia, Fattore, Cinzia, Gasperini, Claudio, Galgani, Simonetta, Haggiag, Shalom, Ruggieri, Serena, Vento, Claudio, Quartuccio, Esmeralda Maria, Pozzilli, Carlo, Barletta, Valeria Teresa, Borriello, Giovanna, De Giglio, Laura, Marinelli, Fabiana, Tasillo, Miriam, Amadori, Alessandra, Fischetti, Mariano, Gurreri, Flavia, Mori, Masahiro, Masuda, Hiroki, Ohtani, Ryohei, Sekiguchi, Yukari, Uchida, Tomohiko, Uzawa, Akiyuki, Ito, Hiromi, Kabasawa, Emi, Kaneko, Yoko, Matsushita, Takuya, Matsuse, Dai, Murai, Hiroyuki, Hayashi, Shintaro, Masak, Katsuhisa, Ogata, Hidenori, Shinoda, Koji, Uehara, Taira, Watanabe, Mitsuru, Yamaguchi, Hiroo, Yamasaki, Ryo, Yonekawa, Tomomi, Jingu, Maki, Nagano, Makiko, Nakamura, Yumiko, Sano, Yoshiko, Araki, Manabu, Lin, Youwei, Mori, Madoka, Mukai, Yohei, Sano, Terunori, Sato, Wakiro, Gogun, Naoya, Maeda, Yuriko, Nishimoto, Asami, Tsukamoto, Sachiko, Yanagi, Ritsuko, Saida, Takahiko, Nakamura, Shinichi, Nasu, Tetsuya, Saida, Kyoko, Shikata, Yuko, Kodani, Yoshimi, Saeki, Megumi, Sawada, Yukako, Yoshikawa, Hiroo, Kimura, Takashi, Nishi, Masamitsu, Sakamoto, Shun, Ukon, Shinichiro, Watanabe, Shohei, Ebisuya, Saori, Kimura, Nami, Matsuura, Manami, Morisaki, Yukie, Muroi, Yoshiko, Onishi, Kuniko, Oshima, Ikuko, Washino, Yuki, Yamashita, Tomomi, Misu, Tatsuro, Kaneko, Kimihiko, Kato, Masaaki, Kuroda, Hiroshi, Kurosawa, Kazuhiro, Nishiyama, Shuhei, Ono, Hirohiko, Takai, Yoshiki, Abe, Keiko, Hoshi, Hitomi, Jinushi, Mari, Oyama, Azusa, Sakuma, Motonari, Sawada, Yuko, Ishibashi, Satoru, Yokota, Takanori, Nishida, Yoichiro, Ozaki, Kokoro, Sanjo, Nobuo, Sato, Nozomu, Denno, Fuki, Hiraki, Haruko, Matsubara, Yumi, Kanda, Takashi, Abe, Masaaki, Honda, Masaya, Kawai, Motoharu, Koga, Michiaki, Maeda, Toshihiko, Ogasawara, Junichi, Omoto, Masatoshi, Sano, Yasuteru, Sato, Ryota, Shimizu, Fumitaka, Arima, Hideki, Fukui, Sachie, Ishikawa, Yoshiko, Koyama, Tomoko, Shimose, Shigemi, Shinozaki, Hirokazu, Watanabe, Masanori, Yasuda, Sachi, Yoshiwaka, Chieko, Adenan, Suffian, Aris, Mohd Azman M, Mawardi, Ahmad Shahir bin, Adnan, Muhammad Al Hafiz, Munusamy, Nanthini, Razali, Siti Nur Omaira, Somasundram, Punitha, Hyun, Jae Won, Jeong, In Hye, Kim, Su-Hyun, Shin, Hyun-June, Yoo, Ji Sung, Jang, HyunMin, Joung, AeRan, Kim, Byung-Jo, Baek, Seol-Hee, Kim, Jung Bin, Kim, Yoo Hwan, Koo, Yong Seo, Lee, Chan Nyoung, Seok, Hung Youl, Hwang, Jinhee, Kim, Sung Min, Ahn, So Hyun, Choi, Kyomin, Choi, Seok-Jin, Kim, Jun-Soon, Kwon, Young Nam, Shin, Je-Young, Kwon, Hyeonju, Kim, Byoung Joon, Cho, Eun Bin, Cho, Hye-Jin, Choi, Misong, Kim, DongSun, Kim, Ju Hyeon, Ki, SeungJu, Lee, Hye Lim, Lee, Kwang-Ho, Min, Ju-Hong, Park, Ji-Hyung, Seok, Jinmyoung, Choi, Eunhwa, Park, Sang Ae, Kim, Seung Min, Jeong, Ha-Neul, Jeongbin, Bong, Jung, Jin Woo, Kim, Seung Woo, Kim, Yool-hee, Lee, Hyung Seok, Shin, Ha Young, Jung, Yeon, Kim, Min Jung, Lee, Nou Ri, Shin, MiJu, Khabirov, Farit A, Averyanova, Lyudmila, Babicheva, Natalya, Granatov, Eugenii, Kazarov, Sergey, Khaybullin, Timur, Rogozhin, Alexander, Pokhabov, Dmitry V, Abramov, Vladislav, Amelina, Anastasia, Nesteroca, Yulia, Bozhenkina, Tatyana, Boyko, Aleksey N, Demyan, Elena G, Khoroshilova, Inessa, Melnikov, Mikhail, Popova, Ekaterina V, Sharanova, Svetlana N, Shchur, Sergey G, Sazonov, Denis V, Babenko, Larisa, Bayandina, Elena, Yarmoschuk, Asya, Baliazin, Victor A, Baliazina, Elena, Budaeva, Elena, Chernikova, Irina, Goncharova, Zoya, Krasnov, Vladimir, Myatleva, Marina, Rodionova, Olga V., Samulyzhko, Iuliana, Timofeeva, Alla A., Duran, Sabas Boyero, Bilbao, Maria Mar Mendibe, Cuervo, Irene Diaz, Domingo, Jose Maria Losada, Eizaguirre, Amaia Gonzalez, Llona, Jose Eulalio Barcena, Moyano, Roberto Valverde, Bahamonde, Carmen, Lopez, Fernando Sanchez, Morales, Raquel Pinar, Morales, Eduardo Agüera, Roman, Carmen Bahamonde, Sepulveda, Juan Jose Ochoa, Valero, Maria del Carmen Blanco, Viña, Nazaret Pelaez, Gavilan, Cristina Conde, Sanchez, Ana Maria Jover, Bedmar, Sara Vila, Garcia, Nuria Gonzalez, Garcia, Aida Orviz, Gonzalez-Suarez, Ines, Guillamon, Elena Miñano, Kawiorski, Miguel, Schulz, Elena Guerra, Alonso, Alba Garcia, Perez, Francisco Jesus Lopez, Sarmiento, Marta Palacios, Ayuso, Guillermo Izquierdo, Mascarell, Guillermo Navarro, Camino, Cristina Paramo, Garcia, Asuncion Varas, Mendoza, Yaiza Montserrat, Muñoz, Veronica Ines Vargas, Tonda, Patricia Torres, Tsai, Ching-Piao, Yin, Jiu-Haw, Chen, Mei-Jung, Li, Shan-Ni, Wang, Fei-Ti, Srisuwannanukorn, Suwat, Boonmongkol, Thanatat, Borisutbuathip, Duangporn, Singwicha, Duangkamol, Siritanan, Krittika, Thearapati, Chidchanoke, Sornda, Kwanmuang, Apiwattanakul, Metha, Aungsumart, Saharat, Suanprasert, Narupat, Suksuchano, Kaona, Parkinsee, Nittaya, Kulkantrakorn, Kongkiat, Lolekha, Praween, Potigumjon, Artit, Sukphulloprat, Puchit, Suksasunee, Dararat, Komaratat, Chankawee, Luangtong, Sunattana, Arayawichanont, Arkhom, Konpan, Phanpaphon, Riablershirun, Nathapol, Wiroteurairuang, Thaddao, Jantaweesirirat, Panadda, Kurne, Aslı, Erkent, Irem, Kurt, Ebru Bekircan, Saylam, Ezgi, Caliskan, Yagmur, Orsel, Gulsah, Celik, Yahya, Celebi, Canan, Tekatas, Aslan, Banbal, Tugce, Demir, Gulsen Akman, Altunrende, Burcu, Matur, Zeliha, Topcular, Baris, Elmas, Tules, Gulo, Aysenur, Ozdemir, Selin, Ozkoklesen, Cansu, Ozturk, Mahinur, Yanik, Mertkan, Yildirim, Elif, Tutuncu, Melih, Altintas, Ayse, Cam, Abdulsamet, Elmali, Ayse Deniz, Saip, Sabahattin, Siva, Aksel, Tanrıverdi, Uygur, Uygunoglu, Ugur, Caliskan, Sinem, Gulo, Pinar, Kozig, Esra, Sakiz, Sakine, Sengun, Ihsan Sukru, Idiman, Egemen, Ala, Rahmi Tumay, Arslan, Duygu, Bulut, Utku, Karakaptan, Yasemin, Kaya, Derya, Mehdiyev, Zaur, Balkan, Bengu, Kuku, Berfu, Ozhun, Mujgan, Tuga, Celal, Ugur, Muzeyyen, Efendi, Husnu, Bunul, Sena Destan, Cavus, Hakan, Gorke, Yunus Emre, Kutlu, Ayse, Ozturk, Seda, Sarikaya, Cansu Egilmez, Becerikli, Gulsah, Semiz, Cansu, Tun, Ozlem, Ayer, Sehriban, Onar, Musa Kazim, Ozberk, Mehlika Berra, Sen, Sedat, Cavdar, Tugce Kirbas, Veske, Adife, Boz, Cavit, Altiparmak, Didem, Aydin, Cigdem Ozen, Gazioglu, Sibel, Bekircan, Duygu, Jacob, Anu, Arndt, Heike, Elsone, Liene, Hamid, Shahd Hassan Mahmoud, Whittam, Daniel Hugh, Wilson, Martin, O'Brien, Imelda, Leite, Maria Isabel da Silva, Cruz, Pedro Maria Rodriguez, Jenkins, Damian Robert, Tackley, George, Cavey, Ana, Everett, Rosie, Hodder, Joy, Koelewyn, Abigail, Mowry, Ellen, Royal, Walter, III, Shin, Robert, Bever, Christopher, Jr, Harrison, Daniel, Rus, Horea, Zheng, Wei, Callison, Karen, Naunton, Kerry, Frishberg, Benjamin M, Blumenfeld, Andrew M, Inocelda, Andrew, Korabathina, Kalyani, Lobatz, Michael, Mortin, Melissa M, Oh, Irene J, Rosenberg, Jay H, Sadoff, Mark, Sahagian, Gregory A, Wang, Anchi, Camberos, Yasmin, Sanchez, Guadalupe, Soto, Estela, Nicholas, Jacqueline A, Boster, Aaron, Eubank, Geoffrey, Groezinger, Katy, Lauf, Meghan, Okai, Annette F, Hasan, Rashedul, Khoury, Chaouki, Stokes, Victoria, Clardy, Stacey, Cortez, Melissa, Greenlee, John, Rose, John, Soldan, Mateo Paz, Emett, Amanda, Esquibel, Lawanda, Fagatele, Lilly, Wong, Ka-Ho, Stevens, James C, Banas, Thomas M, Bultemeyer, Marlene C, Haller, Andrea, Manalo, Natalie, Aeschliman, Keri, Kocks, Debi, Racke, Michael, Boster, Aaron Lee, Bowman, Michelle, Imitola, Jaime, Kisanuki, Yasushi, Green, Misty, Scarberry, Stephanie, Lynch, Sharon G, Anderson, Heather S, Gronseth, Gary S, Hammond, Nancy E, Jassam, Yasir N, Mittal, Manoj K, Nashatizadeh, Muhammed M, Levine, Nicholas, Schmidt, Lisa, Sibley, Jill, Whitley, Vonda, Winkley, James, Coleman, Timothy, Cooper, Gregory, Sheffield, Stephanie, Turner, Keri, Galloway, Dana, Tillett, Robert S, Jr, Ganesh, Geeta A, Plato, Brian M, Seifert, Tad D, Godwin, Diana, Lockridge, Deborah, Rammohan, Kottil W, Sheremata, William A, Delgado, Silvia, Gonzalez, Jose, Lizarraga, Alexis, Maldonado, Janice, Ortega, Melissa, Tornes, Leticia, Babcock, Yanet, Cailam, Osmara, Campos, Yesica, Couvertier, Irlisse, Daneri, Bettina, Deni, Jeremy, Hernandez, Jeffrey, Jaramillo, Tatiana, Morris, Tenita, Nobel, Daniel, Oliveira, Anjelis, Richardson, Reshma, Rodriguez, Gloria, Romero, Ana, Sandova, Carlos, Sawant, Ruta, Tueros, Lissett, Zetka, Eric S, Zheng, Chao, Jacobs, Daniel H, Easterling, Constance, Fairbank, Jennifer, Iyengar, Revathi, Klafter, Mark, Lindquist, Justin, Sadek, Ahmed H, Toro, Elizabeth Carmona, Verma, Navin, Castro, Brigith Patino, Sukhraj-Singh, Nadia, Berger, Joseph, Williamson, Eric, Chahin, Salim, Jacobs, Dina, Markowitz, Clyde, Dobbins, Jessica, Mace, Lauren, Martin, Maria, Pinckney, Ashley, Roberts, Amber, Zaydan, Islam, Mitchell, Galen W, Heyman, Rock A, Orie, Ryan L, Suski, Valerie R, Oddis, Kerry, Punjack, Darlene, Flanagan, Eoin, Gadoth, Avi, McKeon, Andrew, Tobin, W Oliver, Zekeridou, Anastasia, Dunlay, Katie, Sagen, Jessica, Carter, Jonathan L, Estephan, Bachir, Goodman, Brent P, Snyder, Charlene R Hoffman, Francone, Andrea, Galasky, Irene, Thomas, Martha, Repovic, Pavle, Bowen, James, Mayadev, Angeli, Qian, Peiqing, Courtney, Yuriko, Lennox, Lauren, Naismith, Robert Thomas, Cross, Anne Haney, Evans, Emily, Longbrake, Erin E, Orchard, Megan E, Wu, Gregory F, Heinrich, Linda, Sommers, Susan, Amjad, Faria, Mitchell, Erika, Mora, Carlos, Schreiber, Bethany, Tornatore, Carlo, Carlson, Alexis, McCarthy, Sacha, Oliver, Alexandria, Palace, Jacqueline, Wingerchuk, Dean M., Fujihara, Kazuo, Berthele, Achim, Oreja-Guevara, Celia, Kim, Ho Jin, Nakashima, Ichiro, Levy, Michael, Terzi, Murat, Totolyan, Natalia, Viswanathan, Shanthi, Wang, Kai-Chen, Pace, Amy, Yountz, Marcus, Miller, Larisa, Armstrong, Róisín, and Pittock, Sean

Published
2021
Full Text
View/download PDF

21. Safety and Tolerability of Ubrogepant for the Acute Treatment of Migraine in Participants Taking Atogepant for the Preventive Treatment of Episodic Migraine: Results from the TANDEM Trial (S22.005)

Author

Brand-Schieber, Elimor, primary, Lipton, Richard, additional, Blumenfeld, Andrew, additional, He, Molly Yizeng, additional, Smith, Jonathan, additional, Trugman, Joel, additional, de Abreu Ferreira, Rosa, additional, and Ailani, Jessica, additional

Published
2024
Full Text
View/download PDF

25. Long‐term effectiveness of eptinezumab in the treatment of patients with chronic migraine and medication‐overuse headache.

Author

Blumenfeld, Andrew, Kudrow, David, McAllister, Peter, Boserup, Line Pickering, Hirman, Joe, and Cady, Roger

Subjects
*HEADACHE diagnosis, *THERAPEUTIC use of monoclonal antibodies, *MEDICATION overuse headache, *RESEARCH funding, *DATA analysis, *PATIENT safety, *HEADACHE, *QUESTIONNAIRES, *TREATMENT effectiveness, *SEVERITY of illness index, *CHRONIC diseases, *MONOCLONAL antibodies, *STATISTICS, *QUALITY of life, *MEDICAL screening, *HEALTH outcome assessment, *MIGRAINE
Abstract

Objective: This post hoc analysis of the PREVAIL study explored the effectiveness of eptinezumab for up to 2 years of open‐label treatment in the subgroup of patients with chronic migraine who had a confirmed diagnosis of medication‐overuse headache (MOH) at screening. Background: MOH is a disabling and costly secondary headache disorder characterized by increased headache frequency and/or severity with increased acute headache medication use. Eptinezumab, an anti–calcitonin gene‐related peptide monoclonal antibody, reduces headache frequency, severity, and associated disability and improves functioning and health‐related quality of life as a preventive migraine therapy; short‐term benefits in patients with concurrent MOH have also been reported. Methods: Participants received up to eight quarterly intravenous infusions of eptinezumab 300 mg in the phase 3, single‐arm, open‐label PREVAIL study. Safety and patient‐reported outcome measures (Migraine Disability Assessment [MIDAS], 6‐item Headache Impact Test [HIT‐6], patient‐identified most bothersome symptom [PI‐MBS], Patient Global Impression of Change [PGIC], and 36‐item Short‐Form Health Survey [SF‐36]) were conducted at predefined intervals. Patients were observed up to 20 weeks after their last infusion (Week 104). Results: A total of 49/128 (38.3%) patients enrolled in PREVAIL had an MOH diagnosis at screening. In the MOH subgroup, long‐term eptinezumab treatment was associated with reductions in headache frequency (43/49 [87.8%] patients reported ≥50% reduction in MIDAS‐derived headache days at ≥1 visit), severity (2.2‐point reduction [on a 10‐point scale]), disability (mean MIDAS total score reduction of 51.9 points), and impact (mean HIT‐6 total score reduction of 9.7 points) at Week 104. Most patients described a "much improved" or "very much improved" status by Week 48 (PI‐MBS, 31/46 [67.4%]) and Week 104 (PGIC, 31/36 [86.1%]). Health‐related quality of life improvements in the SF‐36 were also observed. Conclusion: Eptinezumab preventive therapy in patients with chronic migraine showed benefits that extended to the subset of patients with concomitant MOH. Plain Language Summary: In this open‐label study, we looked at the effects of eptinezumab in a subset of patients with chronic migraine and medication‐overuse headache (MOH). Our results showed that after 2 years of treatment with eptinezumab, these patients reported that their headache days had decreased by more than half, their headaches were less severe, and that headaches interfered much less with their lives. Eptinezumab preventive therapy in patients with chronic migraine showed benefits for the group of patients with MOH. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Situational prevention: Pharmacotherapy during periods of increased risk for migraine attacks.

Author

Lipton, Richard B., Ailani, Jessica, Mullin, Kathleen, Pavlovic, Jelena M., Tepper, Stewart J., Dodick, David W., and Blumenfeld, Andrew M.

Subjects
MIGRAINE prevention, PATIENT safety, CALCITONIN, NEUROPEPTIDES, DRUG efficacy, MIGRAINE, PREVENTIVE health services, DRUG tolerance, DISEASE risk factors, CHEMICAL inhibitors
Abstract

The small molecule calcitonin gene–related peptide receptor antagonists (gepants) are the only drug class with medicines indicated for both the acute and preventive treatment of migraine. Given this dual capacity to both treat and prevent, along with their favorable tolerability profiles and lack of an association with medication‐overuse headache, headache specialists have begun to use gepants in ways that transcend the traditional categories of acute and preventive treatment. One approach, called situational prevention, directs patients to treat during the interictal phase, before symptoms develop, in situations of increased risk for migraine attacks. Herein, we present three patients to illustrate scenarios of gepant use for situational prevention. In each case, a gepant was started in anticipation of a period of increased headache probability (vulnerability) and continued for a duration of 1 day to 5 consecutive days. Although this approach may expose patients to medication when headache may not have developed, the tolerability and safety profile and preventive effect of gepants may represent a feasible approach for some patients. Situational prevention is an emerging strategy for managing migraine before symptoms develop in individuals who can identify periods when the probability of headache is high. This paper is intended to increase awareness of this strategy and stimulate future randomized, placebo‐controlled trials to rigorously assess this strategy. Plain Language Summary: A new class of migraine medicines, the gepants, does not cause medication‐overuse headache; these drugs can be taken in periods of increased headache risk, even before symptoms begin, to keep headaches from coming on. This new way of treating migraine is called "situational prevention." Experience in clinical practice suggests that treating migraine patients without current symptoms during times of increased headache risk, for example in connection with the menstrual cycle, travel, stress, or relaxation after stress, may be good times for situational prevention, but studies are needed to confirm when this strategy is most likely to be beneficial. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Pharmacology and Pharmacokinetics of Ubrogepant: A Potent, Selective Calcitonin Gene-Related Peptide Receptor Antagonist for the Acute Treatment of Migraine

Author

Blumenfeld, Andrew M., Edvinsson, Lars, Jakate, Abhijeet, and Banerjee, Pradeep

Subjects
Allergan PLC, Ubrelvy (Medication), Drug therapy, Diseases, Calcitonin gene-related peptide receptors, Ubrogepant, Genes, Peptides, Calcitonin, Pharmaceutical industry, Migraine -- Drug therapy
Abstract

KEY TAKEAWAYS * Recognize the role of calcitonin gene-related peptide (CGRP) in the pathogenesis of migraine. * Understand the in vitro and in vivo pharmacokinetic (PK) properties of ubrogepant. * [...]

Published
2020

33. Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial

Author

Lipton, Richard B., Pozo-Rosich, Patricia, Blumenfeld, Andrew M., Li, Ye, Severt, Lawrence, Stokes, Jonathan T., Creutz, Lela, Gandhi, Pranav, Dodick, David, Universitat Autònoma de Barcelona, Institut Català de la Salut, [Lipton RB] Albert Einstein College of Medicine and the Montefiore Headache Center, Bronx, NY. [Pozo-Rosich P] Unitat de Cefalea, Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca de Cefalea i Dolor Neurològic, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma of Barcelona, Bellaterra, Spain. [Blumenfeld AM] Headache Center of Southern California, Carlsbad, CA. [Li Y, Severt L, Stokes JT] AbbVie, Madison, NJ, USA, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Other subheadings::Other subheadings::/prevention & control [Other subheadings], Otros calificadores::Otros calificadores::/prevención & control [Otros calificadores], técnicas de investigación::métodos epidemiológicos::diseño de la investigación epidemiológica::método doble ciego [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::trastornos con cefaleas::cefaleas primarias::trastornos migrañosos [ENFERMEDADES], técnicas de investigación::métodos epidemiológicos::recopilación de datos::encuestas y cuestionarios::encuestas sobre atención a la salud::medidas de resultados percibidos por los pacientes [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Pacients - Satisfacció, Avaluació de resultats (Assistència sanitària), Migranya - Prevenció, Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires::Health Care Surveys::Patient Reported Outcome Measures [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Neurology (clinical), Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Headache Disorders::Headache Disorders, Primary::Migraine Disorders [DISEASES], Investigative Techniques::Epidemiologic Methods::Epidemiologic Research Design::Double-Blind Method [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT]
Abstract

Background and ObjectivesThe oral calcitonin gene–related peptide receptor antagonist atogepant is indicated for the preventive treatment of episodic migraine. We evaluated changes in patient-reported outcomes with atogepant in adults with migraine.MethodsIn this phase 3, 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial (ADVANCE), adults with 4–14 migraine days per month received atogepant (10, 30, or 60 mg) once daily or placebo. Secondary endpoints included changes from baseline in Migraine-Specific Quality-of-Life Questionnaire (MSQ) version 2.1 Role Function–Restrictive (RFR) domain at week 12 and mean monthly Activity Impairment in Migraine–Diary (AIM-D) Performance of Daily Activities (PDA) and Physical Impairment (PI) domains across the 12-week treatment period. Exploratory endpoints included change in MSQ Role Function–Preventive (RFP) and Emotional Function (EF) domains; AIM-D total scores; and change in Headache Impact Test (HIT)–6 scores.ResultsOf 910 participants randomized, 873 comprised the modified intent-to-treat population (atogepant: 10 mg [n = 214]; 30 mg [n = 223]; and 60 mg [n = 222]; placebo [n = 214]). All atogepant groups demonstrated significantly greater improvements vs placebo in MSQ RFR that exceeded minimum clinically meaningful between-group difference (3.2 points) at week 12 (least-square mean difference [LSMD] vs placebo: 10 mg [9.9]; 30 mg [10.1]; 60 mg [10.8]; allp< 0.0001). LSMDs in monthly AIM-D PDA and PI scores across the 12-week treatment period improved significantly for the atogepant 30 (PDA: −2.54;p= 0.0003; PI: −1.99; andp= 0.0011) and 60 mg groups (PDA: −3.32;p< 0.0001; PI: −2.46;p< 0.0001), but not for the 10 mg group (PDA: −1.19;p= 0.086; PI: −1.08;p= 0.074). In exploratory analyses, atogepant 30 and 60 mg were associated with nominal improvements in MSQ RFP and EF domains, other AIM-D outcomes, and HIT-6 scores at the earliest time point (week 4) and throughout the 12-week treatment period. Results varied for atogepant 10 mg.DiscussionAtogepant 30 and 60 mg produced significant improvements in key patient-reported outcomes including MSQ-RFR scores and both AIM-D domains. Nominal improvements also occurred for other MSQ domains and HIT-6, reinforcing the beneficial effects of atogepant as a new treatment for migraine prevention.Trial Registration InformationClinicalTrials.govNCT03777059. Submitted: December 13, 2018; First patient enrolled: December 14, 2018.clinicaltrials.gov/ct2/show/NCT03777059.Classification of EvidenceThis study provides Class II evidence that daily atogepant is associated with improvements in health-related quality-of-life measures in patients with 4–14 migraine days per month.

Published
2022
Full Text
View/download PDF

36. Once-daily oral atogepant for the long-term preventive treatment of migraine:Findings from a multicenter, randomized, open-label, phase 3 trial

Author

Ashina, Messoud, Tepper, Stewart J., Reuter, Uwe, Blumenfeld, Andrew M., Hutchinson, Susan, Xia, Jing, Miceli, Rosa, Severt, Lawrence, Finnegan, Michelle, Trugman, Joel M., Ashina, Messoud, Tepper, Stewart J., Reuter, Uwe, Blumenfeld, Andrew M., Hutchinson, Susan, Xia, Jing, Miceli, Rosa, Severt, Lawrence, Finnegan, Michelle, and Trugman, Joel M.

Abstract

Objective: To assess long-term safety, tolerability, and efficacy of once-daily oral atogepant 60 mg in adults with migraine. Background: Atogepant is an oral, small-molecule, calcitonin gene–related peptide receptor antagonist approved for the preventive treatment of episodic migraine. Methods: A 52-week, multicenter, randomized, open-label trial of adults (18–80 years) with migraine. Lead-in trial completers or newly enrolled participants with 4–14 migraine days/month were enrolled and randomized (5:2) to atogepant 60 mg once daily or oral standard care (SC) migraine preventive medication. The primary objective was to evaluate the safety and tolerability of atogepant; safety assessments included treatment-emergent adverse events (TEAEs), clinical laboratory evaluations, vital signs, and Columbia-Suicide Severity Rating Scale scores. Efficacy assessments (atogepant only) included change from baseline in mean monthly migraine days (MMDs) and the proportion of participants with reductions from baseline of ≥50%, ≥75%, and 100% in MMDs. Results: The trial included 744 participants randomized to atogepant 60 mg (n = 546) or SC (n = 198). The atogepant safety population was 88.2% female (n = 479/543) with a mean (standard deviation) age of 42.5 (12.0) years. TEAEs occurred in 67.0% (n = 364/543) of participants treated with atogepant 60 mg. The most commonly reported TEAEs (≥5%) were upper respiratory tract infection (10.3%; 56/543), constipation (7.2%; 39/543), nausea (6.3%; 34/543), and urinary tract infection (5.2%; 28/543). Serious TEAEs were reported in 4.4% (24/543) for atogepant. Mean (standard error) change in MMDs for atogepant was −3.8 (0.1) for weeks 1–4 and −5.2 (0.2) at weeks 49–52. Similarly, the proportion of participants with ≥50%, ≥75%, and 100% reductions in MMDs increased from 60.4% (310/513), 37.2% (191/513), and 20.7% (106/513) at weeks 1–4 to 84.2% (282/335), 69.9% (234/335), and 48.4% (162/335), at weeks 49–52. Conclusion: Daily use of oral atog

Published
2023

37. Adding eptinezumab to brief patient education to treat chronic migraine and medication-overuse headache:Protocol for RESOLUTION—A phase 4, multinational, randomized, double-blind, placebo-controlled study

Author

Jensen, Rigmor H., Schytz, Henrik Winther, Tassorelli, Cristina, Terwindt, Gisela M., Carlsen, Louise N., Mittoux, Aurélia, Østerberg, Ole, Lipton, Richard B., Tepper, Stewart J., Blumenfeld, Andrew, Lundqvist, Christofer, Jensen, Rigmor H., Schytz, Henrik Winther, Tassorelli, Cristina, Terwindt, Gisela M., Carlsen, Louise N., Mittoux, Aurélia, Østerberg, Ole, Lipton, Richard B., Tepper, Stewart J., Blumenfeld, Andrew, and Lundqvist, Christofer

Abstract

Introduction: Migraine is a highly prevalent and disabling neurological disease. Excessive use of acute medications can lead to medication-overuse headache (MOH), occurring when a patient experiences an increasing number of headache and migraine days, despite taking greater amounts of acute medication. To treat MOH, a preventive migraine treatment and/or withdrawal of the overused medication(s) are advised. Brief Educational Intervention (BEI) has been shown to be an effective tool with promising results for MOH. Here, we report the design of a clinical trial that aims to evaluate the efficacy of eptinezumab, an anti-calcitonin gene-related peptide preventive migraine treatment, as an add-on to BEI for treatment of MOH in those with chronic migraine. Methods and analysis: RESOLUTION will be a phase 4, multi-national, randomized, double-blind, placebo-controlled study. This study will enroll approximately 570 participants with dual diagnoses of chronic migraine and MOH. Eligible patients will be randomly allocated to one of two treatment groups, BEI and eptinezumab (100 mg; n = 285) or BEI and placebo (n = 285), in a 1:1 ratio. The primary endpoint is the change from baseline in monthly migraine days over weeks 1–4. Secondary and exploratory endpoints will assess monthly migraine days over weeks 1–12, MOH remission, transition from chronic to episodic migraine, health-related quality of life, work productivity, and the safety and tolerability of eptinezumab in this patient population. Ethics and dissemination: This study will be conducted in accordance with good clinical practice. All patients will be fully informed about the study, including the risks and benefits of participation, and all participants will provide informed consent for participation in the trial and dissemination of results.

Published
2023

39. Significant reduction in migraine days with Remote Electrical Neuromodulation (REN) for migraine prevention: A double-blind randomized sham-controlled clinical trial (S47.010)

Author

Tepper, Stewart, primary, Rabany, Liron, additional, Cowan, Robert, additional, Smith, Timothy, additional, Grosberg, Brian, additional, Torphy, Brad, additional, Harris, Dagan, additional, Vizel, Maya, additional, Ironi, Alon, additional, Stark-Inbar, Alit, additional, Garas, Sandy, additional, and Blumenfeld, Andrew, additional

Published
2023
Full Text
View/download PDF

41. Adding eptinezumab to brief patient education to treat chronic migraine and medication-overuse headache: Protocol for RESOLUTION—A phase 4, multinational, randomized, double-blind, placebo-controlled study

Author

Jensen, Rigmor H., primary, Schytz, Henrik Winther, additional, Tassorelli, Cristina, additional, Terwindt, Gisela M., additional, Carlsen, Louise N., additional, Mittoux, Aurélia, additional, Østerberg, Ole, additional, Lipton, Richard B., additional, Tepper, Stewart J., additional, Blumenfeld, Andrew, additional, and Lundqvist, Christofer, additional

Published
2023
Full Text
View/download PDF

43. Remote electrical neuromodulation for migraine prevention: A double‐blind, randomized, placebo‐controlled clinical trial

Author

Tepper, Stewart J., primary, Rabany, Liron, additional, Cowan, Robert P., additional, Smith, Timothy R., additional, Grosberg, Brian M., additional, Torphy, Bradley D., additional, Harris, Dagan, additional, Vizel, Maya, additional, Ironi, Alon, additional, Stark‐Inbar, Alit, additional, and Blumenfeld, Andrew M., additional

Published
2023
Full Text
View/download PDF

50. Stressed Utilities: Electricity Demand is Growing Faster Than Projected.

Author

Blumenfeld, Andrew

Subjects
ELECTRIC power consumption, COAL
Abstract

9/ 10/ 24, 10: 53 AM Documenthttps:// davis- media- co. dcatalog. com/ v/ American- Coal- Issue- 1- 2024/? page= 1 50/ 56 9/ 10/ 24, 10: 53 AM Document https:// davis- media- co. dcatalog. com/ v/ American- Coal- Issue- 1- 2024/? page= 1 51/ 56 9/ 10/ 24, 10: 53 AM Document https:// davis- media- co. dcatalog. com/ v/ American- Coal- Issue- 1- 2024/? page= 1 52/ 56 9/ 10/ 24, 10: 53 AM Document https:// davis- media- co. dcatalog. com/ v/ American- Coal- Issue- 1- 2024/? page= 1 54/ 56 [Extracted from the article]

Published
2024

Catalog

Books, media, physical & digital resources
See catalog results